BCL2 and ovarian carcinoma: Several studies have shown that ALKBH5 inhibits Bcl2 degradation by reducing m6A modification, thereby regulating cell apoptosis in ovarian cancer, hepatocellular carcinoma and cerebral ischemia-reperfusion injury [17,18,19].